Alector Phase 1b Data Demonstrates Progranulin Deficit Reversal in Dementia

– AL001 was seen to be generally safe and well-tolerated based on the results of the Phase 1 portion of the INFRONT clinical study

– AL001 elicited an increase in the level of progranulin to normal range in the plasma and CSF of frontotemporal dementia patients carrying a granulin mutation in the Phase 1b portion of the INFRONT clinical study

https://www.marketscreener.com/ALECTOR-INC-54379343/news/Alector-Announces-Data-from-On-going-Phase-1b-Trial-Demonstrating-that-AL001-Reverses-Progranulin-De-28918513/